Recent News

• 02.12.2026 - Calidi Biotherapeutics To Present on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform in a Late-Breaking Abstract at the 2026 AACR-IO Conference
• 01.28.2026 - Calidi Biotherapeutics Provides Corporate Update and Key Value Drivers for 2026
• 11.10.2025 - Calidi Biotherapeutics Presents New Data on its Therapeutic Lead, CLD-401, at the 2025 SITC Annual Meeting and Holds Its First Investor Day at SITC
• 11.04.2025 - Calidi Biotherapeutics Announces Investor Event to be Held on Friday, November 7th at the 2025 SITC Annual Meeting
• 10.30.2025 - Calidi Biotherapeutics Announces New Data to be Presented on its Therapeutic Lead, CLD-401, at the 2025 SITC Annual Meeting

Recent Filings

• 02.10.2026 - EX-99.1 EX-99.1
• 02.10.2026 - 8-K Current report
• 02.10.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.04.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 01.29.2026 - 8-K Current report
• 01.29.2026 - EX-99.1 EX-99.1
• 12.16.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.13.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.13.2025 - EX-99.1 EX-99.1
• 11.13.2025 - 8-K Current report